Atrasentan hydrochloride

Overview

Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC 50 of 0.0551 nM for ET A .

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pain | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hypertension | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Endothelin Receptor

Product Information

• Catalog No.: HY-15403A
• CAS No.: 195733-43-8
• Molecular Formula: C29H39ClN2O6
• Molecular Weight: 547.08
• Purity: 99.82%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution
• Availability: In-stock

Source

Original product source